Tuesday, September 2, 2014

PGx of anti-HIV drug described in new PharmGKB pathway

Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used as part of a highly active anti-retroviral therapy (HAART) regimen against HIV-1 infection. Large variability in EFV plasma levels is observed between patients given the same dose. Genetic variants underlying EFV metabolism have been shown to contribute to this variability.

A new PharmGKB pathway depicts the inhibitory action of EFV on HIV replication in T cells and the genes involved in metabolism of the drug in human hepatocytes. Associations between variants in these genes and EFV exposure, toxicity and efficacy are discussed in the pathway description.